Module 5: Lipid Management

Alan Chait, MD

  • Pathophysiology & Vascular Biology
  • Classification, Measurement and Metabolism of Lipids and Lipoproteins
  • Cholesterol, lipoproteins, and ASCVD risk

Screening and Treatment of Hypercholesterolemia
Christie M. Ballantyne, MD; Maya Vadiveloo, PhD, RD; Pam R. Taub, MD

  • ASCVD risk factors & risk enhancers
  • Identification, testing and ASCVD risk assessment
  • Lifestyle modifications for lipid lowering
  • Pharmacologic treatment (current guidelines, efficacy and safety of statin and non-statin therapies)

Residual ASCVD Risk 
Robert H. Eckel, MD

  • Hypertriglyceridemia: Association or causative for ASCVD management
  • HTG targets
  • Review of HTG management strategies, from moderate to severe HTG
  • HDL and HDL science/management

Other Players in Dyslipidemia (Optional/Not for Credit) 
Sotirios Tsimikas, MD

  • Lipoprotein (a) science/evidence/management, emerging therapies

Target Audience

The Foundations of Cardiometabolic Health Certification Course is appropriate for clinicians from a full spectrum of clinical experience including Physicians, Physician Assistants, Nurse Practitioners, Registered Nurses, Pharmacists, Diabetologists, and Dietitians who are in any phase of training, or even experienced physicians who are looking to take a deeper dive into cardiometabolic health.

Learning Objectives

After completing this activity, the participant should be better able to:

  • List current and emerging treatment options for lipid lowering, including for hypercholesterolemia, hypertriglyceridemia, and elevated lipoprotein a.
  • Recognize the burden of other lipid players beyond LDL-C in the development of atherosclerosis and residual ASCVD risk.
  • Develop individualized treatment options for patients with dyslipidemia based on current treatment options and guideline recommendations.

Additional Information

PDF icon Resources: Module 5 - Lipid Management518.35 KB
Course summary
Available credit: 
  • 6.00 ABIM MOC and AMA PRA Category 1 Credit
  • 6.00 ACPE Pharmacy
  • 6.00 AMA PRA Category 1 Credit
  • 6.00 ANCC
  • 6.00 CDE
  • 6.00 Participation
Course opens: 
Course expires: 

Alan Chait MD
Professor Emeritus
University of Washington 
Seattle, WA

Dr. Chait discloses the following:
Consultant: Pfizer, LIB

Christie M. Ballantyne, MD
Professor of Medicine, Baylor College of Medicine
Professor, Molecular and Human Genetics
Professor, Molecular Physiology and Biophysics
Director, The Maria and Alando J. Ballantyne, M.D. Atherosclerosis Clinical Research Laboratory
Director, Center for Cardiometabolic Disease Prevention
Co-Director, Lipid Metabolism and Atherosclerosis Clinic
J. S. Abercrombie Chair - Atherosclerosis and Lipoprotein Research
Chief of Cardiology
Chief of Cardiovascular Research
Baylor College of Medicine
Houston, TX

Dr. Ballantyne discloses the following:
Research Support (All paid to institution, not individual): Abbott Diagnostic, Akcea, Amgen, Esperion, Ionis, Novartis, Regeneron, Roche Diagnostic
Consultant:  Abbott Diagnostics, Althera, Amarin, Amgen, Arrowhead, AstraZeneca, Corvidia, Denka Seiken, Esperion, Genentech, Gilead, Matinas BioPharma Inc, New Amsterdam, Novartis, Novo Nordisk, Pfizer, Regeneron, Roche Diagnostic, Sanofi-Synthelabo

Maya Vadiveloo, PhD RD FAHA
Associate Professor of Nutrition and Food Sciences
University of Rhode Island

Dr. Vadiveloo has no relevant financial relationships to disclose.

Pam R. Taub MD, FACC
Founder and Director of Step Family
Cardiac Rehabilitation and Wellness Center
Professor of Medicine
UC San Diego Health System

Dr. Taub discloses the following:
Consultant: Sanofi, Novo-Nordisk, Novartis, Boehringer-Ingelheim, Amgen, Bayer, Medtronic, Merck, Edwards and Esperion
Stockholder: Epirium Bio
Research Support: NIH, Department of Homeland Security, Hillblom Foundation Network, AHA

Robert H. Eckel, MD, FAHA, FACC
Professor of Medicine, Emeritus
Division of Endocrinology, Metabolism and Diabetes
Division of Cardiology
S/P Charles A. Boettcher II Chair in Atherosclerosis
University of Colorado Anschutz Medical Campus

Dr. Eckel discloses the following:
Consultant: Amarin, Kowa, Kaleido, Novo Nordisk, Prevention Bio, The Healthy Aging Co., Weight Watchers

Sotirios Tsimikas, MD*
Director of Vascular Medicine
Professor of Medicine
University of California San Diego

Dr. Tsimikas discloses the following: 
Salary: Ionis
Royalty/Receipt of Intellectual Property Rights/Patent Holder: UCSD
Consulting/Contracted Research: Novartis
Stockholder: Kleanthi Dx, Oxitope Inc, Covicept Therapeutics

*Dr. Tsimikas' presentation is optional/not for credit

6 hours


In support of improving patient care, this activity has been planned and implemented by Partners for Advancing Clinical Education (PACE) and Tarsus Cardio Inc. dba Cardiometabolic Health Congress (CMHC). PACE is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Partners for Advancing Clinical Education designates this enduring material for a maximum of 6 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

The maximum number of hours awarded for this Continuing Nursing Education activity is 6 contact hours. Pharmacotherapy contact hours for Advanced Practice Registered Nurses will be designated on your certificate.

Partners for Advancing Clinical Education designates this continuing education activity for 6 contact hour(s) (0.6 CEUs) of the Accreditation Council for Pharmacy Education.

This is an application-based activity. Universal Activity Numbers (UAN): JA4008073-9999-22-005-H01-P

For Pharmacists: Upon completing the post-test and the activity evaluation form, transcript information will be sent to the NABP CPE Monitor Service within 4 – 6 weeks.

This program offers 6 CPEUs for dieticians.


Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 6 MOC points in the American Board of Internal Medicine's (ABIM) maintenance of certification (MOC) program. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.


Completion of this accredited CME activity meets the expectations of an Accredited Safety or Quality Improvement Program (IA_PSPA_28) for the Merit-based Incentive Payment Program (MIPS).

Partners for Advancing Clinical Education (PACE) requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose all financial conflicts of interest (COI) they may have with ineligible companies. All relevant COI are thoroughly vetted and mitigated according to PACE policy. PACE is committed to providing learners with high-quality accredited CE activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company.

The PACE planners and others have nothing to disclose. The CMHC planners and others have nothing to disclose.

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA.  The planners of this activity do not recommend the use of any agent outside of the labeled indications.  The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners.  Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management.  Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient's conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer's product information, and comparison with recommendations of other authorities.

During the period March 11, 2022 through June 24, 2023, participants must read the learning objectives and faculty disclosures, study the educational activity, obtain a score of 75% or better on the post-test, and complete the evaluation. Upon completing, your certificate will be available for print. For questions about receiving certificates, please contact us at

For questions about the accreditation of this activity, please visit

For Pharmacists: Please complete the evaluation instructions above. Upon registering and completing the activity evaluation, your transcript information will be sent to the NABP CPE Monitor Service within 4-6 weeks.

1) Complete this module post-test and evaluation.
2) Over the next 90 days, actively work to incorporate improvements in your clinical practice from these presentations.
3) Complete the follow-up survey from CMHC in approximately 90 days.

Available Credit

  • 6.00 ABIM MOC and AMA PRA Category 1 Credit
  • 6.00 ACPE Pharmacy
  • 6.00 AMA PRA Category 1 Credit
  • 6.00 ANCC
  • 6.00 CDE
  • 6.00 Participation
Please login or register to take this course.
Please login or register to take this course.
Please login or register to take this course.
Please login or register to take this course.
Please login or register to take this course.
Please login or register to take this course.
Please login or register to take this course.

Required Hardware/software

A computer with an internet connection

Internet Browser: Internet Explorer 7.x or higher, Firefox 4.x or higher, Safari 2.x or higher, or any other W3C standards compliant browser

Other additional software may be required such as PowerPoint or Adobe Acrobat Reader.